Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | HOOK |
---|---|---|
09:32 ET | 53240 | 0.996 |
09:34 ET | 110595 | 0.949551 |
09:36 ET | 130946 | 0.9097 |
09:38 ET | 33524 | 0.911 |
09:39 ET | 20221 | 0.915 |
09:41 ET | 8810 | 0.9101 |
09:43 ET | 10737 | 0.9098 |
09:45 ET | 29403 | 0.9362 |
09:48 ET | 4992 | 0.92 |
09:50 ET | 3638 | 0.9201 |
09:52 ET | 300 | 0.9202 |
09:54 ET | 3512 | 0.9283 |
09:56 ET | 1799 | 0.93619 |
09:57 ET | 100 | 0.9302 |
09:59 ET | 8019 | 0.935 |
10:01 ET | 6424 | 0.9345 |
10:03 ET | 2512 | 0.9331 |
10:06 ET | 1166 | 0.9301 |
10:08 ET | 7238 | 0.93949 |
10:10 ET | 1500 | 0.93 |
10:12 ET | 16680 | 0.9201 |
10:14 ET | 12384 | 0.91 |
10:15 ET | 14112 | 0.906 |
10:17 ET | 22030 | 0.9098 |
10:19 ET | 1400 | 0.9165 |
10:21 ET | 2600 | 0.92055 |
10:24 ET | 10670 | 0.9284 |
10:26 ET | 100 | 0.9185 |
10:28 ET | 8928 | 0.9018 |
10:30 ET | 10379 | 0.9018 |
10:32 ET | 1100 | 0.902 |
10:33 ET | 25523 | 0.9018 |
10:35 ET | 18985 | 0.89 |
10:37 ET | 23486 | 0.88 |
10:39 ET | 28193 | 0.87 |
10:42 ET | 51462 | 0.8801 |
10:44 ET | 28912 | 0.87 |
10:46 ET | 29819 | 0.8873 |
10:48 ET | 3500 | 0.8766 |
10:50 ET | 21663 | 0.87 |
10:51 ET | 74762 | 0.8328 |
10:53 ET | 13024 | 0.8491 |
10:55 ET | 4272 | 0.854899 |
10:57 ET | 4029 | 0.8554 |
11:00 ET | 9235 | 0.8875 |
11:02 ET | 21980 | 0.855 |
11:04 ET | 6281 | 0.8524 |
11:06 ET | 6951 | 0.842501 |
11:08 ET | 10748 | 0.8419 |
11:09 ET | 21762 | 0.8413 |
11:11 ET | 14145 | 0.8395 |
11:13 ET | 3735 | 0.8561 |
11:15 ET | 10700 | 0.843 |
11:18 ET | 52709 | 0.8234 |
11:20 ET | 36017 | 0.83 |
11:22 ET | 4289 | 0.8301 |
11:24 ET | 10274 | 0.83 |
11:26 ET | 3789 | 0.83 |
11:27 ET | 12268 | 0.8305 |
11:29 ET | 4453 | 0.8301 |
11:31 ET | 626 | 0.830318 |
11:33 ET | 1031 | 0.8302 |
11:36 ET | 7089 | 0.846345 |
11:38 ET | 11672 | 0.849899 |
11:40 ET | 7980 | 0.85 |
11:44 ET | 1650 | 0.857 |
11:45 ET | 1846 | 0.855 |
11:47 ET | 2097 | 0.8539 |
11:49 ET | 300 | 0.85345 |
11:51 ET | 12112 | 0.85 |
11:54 ET | 9381 | 0.8367 |
11:56 ET | 3340 | 0.8329 |
11:58 ET | 100 | 0.836 |
12:00 ET | 1550 | 0.8375 |
12:02 ET | 6679 | 0.84 |
12:03 ET | 100 | 0.8375 |
12:05 ET | 27708 | 0.83 |
12:07 ET | 4834 | 0.8302 |
12:09 ET | 1179 | 0.8305 |
12:12 ET | 500 | 0.847 |
12:14 ET | 5000 | 0.8425 |
12:16 ET | 487 | 0.841 |
12:18 ET | 200 | 0.841 |
12:20 ET | 20964 | 0.832 |
12:21 ET | 35349 | 0.8274 |
12:23 ET | 17169 | 0.82 |
12:25 ET | 9637 | 0.8236 |
12:27 ET | 43097 | 0.8177 |
12:30 ET | 19270 | 0.8207 |
12:32 ET | 9700 | 0.8399 |
12:34 ET | 11450 | 0.824 |
12:36 ET | 21089 | 0.825 |
12:38 ET | 49477 | 0.82 |
12:39 ET | 4086 | 0.8195 |
12:41 ET | 16700 | 0.8199 |
12:43 ET | 300 | 0.8196 |
12:45 ET | 10639 | 0.8372 |
12:48 ET | 3200 | 0.8368 |
12:50 ET | 100 | 0.837 |
12:52 ET | 33054 | 0.82 |
12:54 ET | 39297 | 0.84 |
12:56 ET | 17643 | 0.830101 |
12:57 ET | 26648 | 0.8236 |
12:59 ET | 12910 | 0.8229 |
01:01 ET | 200 | 0.838 |
01:03 ET | 2300 | 0.827054 |
01:06 ET | 11300 | 0.83 |
01:08 ET | 10000 | 0.8374 |
01:10 ET | 2822 | 0.8337 |
01:12 ET | 1204 | 0.8373 |
01:14 ET | 5602 | 0.8301 |
01:15 ET | 1877 | 0.8373 |
01:17 ET | 730 | 0.8324 |
01:19 ET | 1000 | 0.835101 |
01:21 ET | 300 | 0.836 |
01:24 ET | 2080 | 0.8373 |
01:26 ET | 6388 | 0.8373 |
01:28 ET | 19789 | 0.8488 |
01:30 ET | 7576 | 0.8402 |
01:32 ET | 3000 | 0.8487 |
01:33 ET | 2986 | 0.8326 |
01:35 ET | 200 | 0.8487 |
01:37 ET | 700 | 0.8487 |
01:39 ET | 120 | 0.842699 |
01:42 ET | 6000 | 0.84 |
01:44 ET | 2479 | 0.8325 |
01:48 ET | 200 | 0.84 |
01:50 ET | 100 | 0.8325 |
01:51 ET | 973 | 0.8399 |
01:53 ET | 11708 | 0.8399 |
01:55 ET | 3000 | 0.8398 |
01:57 ET | 5197 | 0.83549 |
02:00 ET | 3753 | 0.833255 |
02:02 ET | 844 | 0.833 |
02:04 ET | 3444 | 0.8438 |
02:06 ET | 646 | 0.8436 |
02:08 ET | 1400 | 0.838349 |
02:09 ET | 300 | 0.83835 |
02:11 ET | 849 | 0.84 |
02:13 ET | 6897 | 0.841 |
02:15 ET | 4333 | 0.84 |
02:18 ET | 1600 | 0.8445 |
02:20 ET | 2200 | 0.8488 |
02:22 ET | 1300 | 0.8488 |
02:24 ET | 7233 | 0.8594 |
02:27 ET | 5000 | 0.850549 |
02:29 ET | 6963 | 0.86049 |
02:31 ET | 1550 | 0.8597 |
02:36 ET | 3125 | 0.86 |
02:38 ET | 4600 | 0.85 |
02:44 ET | 2000 | 0.8591 |
02:45 ET | 6575 | 0.8591 |
02:47 ET | 100 | 0.8513 |
02:49 ET | 2392 | 0.8591 |
02:51 ET | 5758 | 0.855 |
02:54 ET | 6087 | 0.8524 |
02:56 ET | 200 | 0.8591 |
03:00 ET | 520 | 0.859 |
03:02 ET | 150 | 0.8545 |
03:03 ET | 1250 | 0.85 |
03:05 ET | 12023 | 0.8488 |
03:07 ET | 1886 | 0.8498 |
03:09 ET | 471 | 0.84985 |
03:12 ET | 5927 | 0.8498 |
03:14 ET | 2500 | 0.8499 |
03:18 ET | 200 | 0.8499 |
03:20 ET | 5034 | 0.8499 |
03:21 ET | 3500 | 0.8499 |
03:23 ET | 1150 | 0.8499 |
03:25 ET | 200 | 0.85 |
03:27 ET | 400 | 0.8495 |
03:30 ET | 581 | 0.8475 |
03:32 ET | 200 | 0.845 |
03:34 ET | 1767 | 0.8475 |
03:36 ET | 12142 | 0.845 |
03:38 ET | 2400 | 0.8486 |
03:39 ET | 300 | 0.8479 |
03:41 ET | 4462 | 0.8475 |
03:43 ET | 15718 | 0.84 |
03:45 ET | 11851 | 0.842 |
03:48 ET | 400 | 0.841 |
03:50 ET | 1233 | 0.84 |
03:52 ET | 2318 | 0.840101 |
03:54 ET | 2582 | 0.8401 |
03:56 ET | 10170 | 0.8499 |
03:57 ET | 185293 | 0.79 |
03:59 ET | 83982 | 0.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
HOOKIPA Pharma Inc | 79.2M | 0.0x | --- |
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $79.2M |
---|---|
Revenue (TTM) | $53.6M |
Shares Outstanding | 99.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-0.59 |
Book Value | $0.91 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -119.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.